AF9 Antikörper (N-Term)

Produktnummer ABIN390130

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch AF9 in WB. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für AF9 Antikörper (N-Term) (ABIN390130)

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AF9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: RB6802

Produktdetails anti-AF9 Antikörper

Bindungsspezifität: AA 39-65, N-Term

Homologie: M

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This MLLT3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-65 amino acids from the N-terminal region of human MLLT3.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Haltbarkeit: 6 months

Details zu AF9

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Andere Bezeichnung: MLLT3

Hintergrund: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

Molekulargewicht: 63351

Gen-ID: 4300

NCBI Accession: NP_004520

UniProt: P42568